Schema of constructs used in the study. Genes for mature sequences of murine MIP-3α and DF2β, or viral chemokines vMIP2, MC148, and US83 were fused in-frame with DNA encoding either sFv38 from 38C13 or V_L from MOPC315 mouse B-cell tumors. B-cell lymphoma patient LF's sFv (sFvLF) was fused with human MIP-3α (hMIP3αsFvLF). Control constructs encoded chemokines with point mutation, which abrogated chemokine receptor binding (MIP3αM-VL315, MC148M-VL315, MC148M-sFv38, hMDCM-sFv3816 and vMIP2M-sFv38, respectively), or chemokine genes fused with an irrelevant antigen, human breast cancer Muc1 (vMIP2-Muc1 and MCP3-Muc115,16), or inactive pro–β-defensin 2 (proDF2βsFv3816). To enable purification and detection, c-myc and His peptide tags were fused to COO end of constructs (Tag). For DNA vaccines (not shown), fusion constructs were in-frame fused with signal sequence (SL) from murine IP-10 gene or contained native SL (vMIP2 and MC148 constructs only) to enable protein secretion, and constructs were cloned in pcDNA3.1 (Invitrogen).15,16 Spacer fragment (SP) was inserted between chemoattractant and antigen moieties to enable proper folding of the proteins. Recombinant proteins are depicted for (A) MOPC315 plasmacytoma construct; (B) 38C-lymphoma construct; and (C) human lymphoma or other constructs.